Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTS167PO in Advanced Breast Cancer and TNBC
NCT02926690Phase 1Recruiting
- Sponsor
- OncoTherapy Science, Inc.
- Start
- May 2017
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OTS167 in breast cancer and triple-negative breast cancer (TNBC), sponsored by OncoTherapy Science, Inc. Primary endpoint: Maximum Tolerated Dose at Cycle 1. Started May 2017; status: recruiting.
02
Drugs
OTS167
03
Conditions
breast cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02926690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926690.